References
- Stewart AK, Rajkumar SV, Dimopoulos MA, et al., Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372(2): 142–152.
- Lonial S, Dimopoulos MA, Palumbo A, et al., Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015; 373(7): 621–631.
- Dimopoulos MA, Oriol A, Nahi A, et al. Daratumumab, lenalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375:1319–1331.
- Moreau P, Masszi T, Grzasko N, et al., Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 374(17): 1621–1624.
- Chari A, Romanus D, Palumbo A, et al. Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma. 2020 Jan;20(1):8–17.e16.
- Schutz N, Ochoa P, Duarte P, et al. Real world outcomes with VTD andCyBorD induction treatment for transplant eligible multiple myeloma patients in a Latin American country. Hematol Oncol. 2020 Aug;3:363.
- Sociedad Argentina de Hematologia. Guias de diagnostico y tratamiento.Gammapatias monoclonales 2019. http://www.sah.org.ar/guias_hematolo_2019.asp. Accessed Aug, 2020.
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
- Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–6.
- Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 4.03, DCTD, NCI, NIH, DHHS, June 14, 2010. Ref Type: Online Source.
- Bringhen S, Milan A, Ferri C, et al. Cardiovascular adverse events in modern myeloma therapy- incidence and risks. A review from the European myeloma network (EMN) and Italian society of arterial hypertension (SIIA). Haematologica. 2018 Sep;103(9):1422.
- Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Adv. 2017;1(7):449–454.
- Bruno G, Bringhen S, Maffei LL, et al. Cardiovascular organ damage and blood pressure levels predict adverse events in multiple myeloma patients undergoing carfilzomib therapy. Cancers (Basel). 2019 May;11(5):622.
- Moreau P, Zamagni E, Mateos MV. Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide. Blood Cancer J. 2019;9(38):1–8.
- Chari A, Richardson PG, Romanus D, et al. Real world outcomes and factors impacting choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd and IRd. Exp Rev of Hematol. 2020;13(4):421–423.
- Richardson PG, Xie P, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014;123(10):1461–1469.
- Kaufman J, Usmani S, San-Miguel J, et al. Four-year follow-up of the phase 3 Pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in relapsed or refractory multiple myeloma (RRMM). Blood. 2019;134(Supplement_1):1866.
- Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report. Blood. 2015;125(13):2068–2074.
- Kastritis E, Roussou M, Gavriatopoulou M, et al. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. Blood Adv. 2019;3(23):4095–4103.